How Much Could Moderna Stock Give Back?
For questions about this article or underlying research, email help@trefis.com.
Moderna (MRNA) stock returned 736.3% over the twelve months to November 13, 2026, compared with 11.7% for the S&P 500. Some of those gains have already faded. The shares closed at $223.37 on November 13, sitting 17.0% below their November 9 high. If the market turns, how far has Moderna fallen in past sell-offs, and how long did it stay down?

How Far Has Moderna Stock Fallen In Market Shocks?
On average, Moderna has fallen about twice as far as the market: in the seven market shocks it has traded through since it listed in 2018, the stock fell 31.4%, against 15.9% for the S&P 500. Its largest fall came in the 2022 inflation shock and Fed tightening, when it lost 50.0% while the S&P 500 lost 24.0%. The 2020 COVID-19 crash was milder for Moderna: it fell 3.6% as the S&P 500 lost 34.0%.
Recovering those losses has often taken a long time. The median recovery took 8.0 months from the low, but three of the seven took more than a year. After the 2022 fall, Moderna did not regain its peak close until October 15, 2026, which was 52.1 months after the low.
Market shocks were not Moderna’s worst stretch, either. The stock lost 95.4% between its close on August 9, 2021 and its close on November 20, 2025.
Moderna’s Sales Are Growing Again, From A Smaller Base
Moderna generated revenue of $2.52 billion over the twelve months to September 30, 2026, up 14.4% from a year earlier. That figure represents a fraction of the $20.7 billion the company recorded over the twelve months to September 30, 2022.
The company still lost money over those twelve months, reporting an operating margin of -116.3%, compared with -157.3% a year earlier. The latest quarter broke that pattern. Moderna earned a net profit of $162 million in fiscal Q3 2026, compared with a $200 million loss a year earlier.
Most of Moderna’s sales still come from one product line. During fiscal 2025, COVID vaccines brought in $1.81 billion of its $1.92 billion in revenue. On the balance sheet, Moderna holds more cash than debt. The company reported $5.17 billion of cash and short-term investments on September 30, 2026, against $4.23 billion of debt.
Where Is Moderna’s Business Under Pressure Now?
During its November 6, 2026 call, management said COVID-19 vaccinations in U.S. retail and long-term care channels were trending slightly behind last year through late October. October’s pace, though, suggested they may end up flat.
Moderna’s norovirus vaccine has stalled. The phase 3 study did not meet the statistical criteria for early success at its interim analysis. On the same call, management said Moderna will not enroll an additional cohort for the coming winter season and is asking health authorities for next steps instead.
A legal settlement is also adding to Moderna’s costs. Management expects cost of sales of $1.7 billion for 2026, a figure that includes a $900 million litigation settlement charge.
Moderna’s full-year 2026 revenue, against management’s guide of 15% to 25% growth, is the number to watch when the company reports in February 2027. That guide implies $2.21 billion to $2.40 billion, below the $2.52 billion of the latest twelve months, so fourth-quarter sales would fall from a year earlier.
Want Income That Doesn’t Hang On One Company?
Every single stock carries risks like these. The Trefis Income Solution spreads your money across 50 companies chosen to keep paying dividends, each with at least 10 straight years of dividends, with a yield about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.